The quantitative analysis of cidofovir and famciclovir using a Symmetry C-18 150x4.6mm, 3.5 column with a flow rate of 1ml/min has resulted in the development of a brand-new, effective, and exact high performance liquid chromatographic method. Acetonitrile and buffer are mixed in 60:40 ratios for the mobile stage, and the buffer is created by dissolving 1 mL of formic acid in 1 liter of HPLC water. The detection was done at a wavelength of 250 nm. After 8 minutes of running time, the Cidofovir and Famciclovir peaks were separated, with the former peak eluting after 2.8 minutes and the latter peak eluting after 6.4 minutes, respectively.The proposed method displays strong linearity in the concentration ranges of 7.5 g/ml to 112.5 g/ml for cidofovir and 25 g/ml to 375 g/ml for famciclovir. The findings of the precision and recovery examinations range from 98 to 102%. The percent RSD is less than 2.0% in any robustness scenario. Under pressure, deterioration has little impact, and solutions remain effective for the entire day. The parameters of precision, accuracy, specificity, stability, robustness, linearity, limit of detection, and limit of quantification were evaluated and found to be within the acceptable range when the method was devised and validated in accordance with ICH guidelines.
{"title":"A brand-new efficient and precise high performance liquid Chromatographic Method for Simultaneous Estimation of Cidofovir and Famciclovir","authors":"Rafi Syed, Kirankumar Ch, Gidyonu Paleti","doi":"10.37022/jiaps.v8i3.504","DOIUrl":"https://doi.org/10.37022/jiaps.v8i3.504","url":null,"abstract":"The quantitative analysis of cidofovir and famciclovir using a Symmetry C-18 150x4.6mm, 3.5 column with a flow rate of 1ml/min has resulted in the development of a brand-new, effective, and exact high performance liquid chromatographic method. Acetonitrile and buffer are mixed in 60:40 ratios for the mobile stage, and the buffer is created by dissolving 1 mL of formic acid in 1 liter of HPLC water. The detection was done at a wavelength of 250 nm. After 8 minutes of running time, the Cidofovir and Famciclovir peaks were separated, with the former peak eluting after 2.8 minutes and the latter peak eluting after 6.4 minutes, respectively.The proposed method displays strong linearity in the concentration ranges of 7.5 g/ml to 112.5 g/ml for cidofovir and 25 g/ml to 375 g/ml for famciclovir. The findings of the precision and recovery examinations range from 98 to 102%. The percent RSD is less than 2.0% in any robustness scenario. Under pressure, deterioration has little impact, and solutions remain effective for the entire day. The parameters of precision, accuracy, specificity, stability, robustness, linearity, limit of detection, and limit of quantification were evaluated and found to be within the acceptable range when the method was devised and validated in accordance with ICH guidelines.","PeriodicalId":477216,"journal":{"name":"Journal of innovations in applied pharmaceutical sciences","volume":"86 11","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136232026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The disease Hansen's is another name for leprosy. It is a communicable disease that can be treated and is still widespread in the majority of the world's nations. Mycobacterium leprae and Mycobacterium lepromatosis are the most common causes of this chronic granulomatous infection, which mostly affects the skin and peripheral nerves.Leprosy has long been known as "the death before death" because of the immense social stigma and rejection that victims have endured from their families, communities, and even medical professionals in addition to the physical effects of the condition. Armauer Hansen, who discovered Mycobacterium leprae, stated that "there is hardly anything on earth, or between it and heaven, that has not been regarded as the cause of leprosy." "And this is but natural since the less one knows, the more actively does his imagination work"MDT has been the main weapon in the fight against leprosy since its inception in 1981, and by 2005, India had a prevalence of less than 1/10000. In India's fight against leprosy, this was a huge victory. Affected individuals numbered 0.69/10000 by the end of 2010.The pathogenesis, aetiology, treatment, diagnosis, and risk factors for leprosy are covered in this review article.
{"title":"Overview of leprosy, including the diagnosis and current available treatments","authors":"Yash Srivastav, Akhandnath Prajapati, Aayushi Jaiswal, Sony Yadav, Adityanath Prajapati, Kumar Madhaw","doi":"10.37022/jiaps.v8i3.495","DOIUrl":"https://doi.org/10.37022/jiaps.v8i3.495","url":null,"abstract":"The disease Hansen's is another name for leprosy. It is a communicable disease that can be treated and is still widespread in the majority of the world's nations. Mycobacterium leprae and Mycobacterium lepromatosis are the most common causes of this chronic granulomatous infection, which mostly affects the skin and peripheral nerves.Leprosy has long been known as \"the death before death\" because of the immense social stigma and rejection that victims have endured from their families, communities, and even medical professionals in addition to the physical effects of the condition. Armauer Hansen, who discovered Mycobacterium leprae, stated that \"there is hardly anything on earth, or between it and heaven, that has not been regarded as the cause of leprosy.\" \"And this is but natural since the less one knows, the more actively does his imagination work\"MDT has been the main weapon in the fight against leprosy since its inception in 1981, and by 2005, India had a prevalence of less than 1/10000. In India's fight against leprosy, this was a huge victory. Affected individuals numbered 0.69/10000 by the end of 2010.The pathogenesis, aetiology, treatment, diagnosis, and risk factors for leprosy are covered in this review article.","PeriodicalId":477216,"journal":{"name":"Journal of innovations in applied pharmaceutical sciences","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135759744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sireesha Badri, Ravi Kumar J, Siva P, Pavan M, Basheer K, Ashok E, Lavanya B
The analytical method should be sensitive, specific, fast and accurate to establish the assurance that the equipments used in manufacturing are free of the unwanted impurity, presence of which may alter the safety and efficacy of the drug product. HPLC, UPLC techniques have established their role in pharmaceutical cleaning validation. Among the modern Analytical tools HPTLC is a powerful analytical method equally suitable for qualitative and quantitative analytical tasks. HPTLC is playing an important role in today analytical world, not in competition to HPLC but as a complementary method. One of the most obvious orthogonal features of the two techniques is the primary use of reversed phases in HPLC versus unmodified silica gel in HPTLC, resulting in partition chromatography and adsorption chromatography respectively. High Performance Thin layer Chromatography (HPTLC) technique is a sophisticated and automated form of the thin-layer chromatography (TLC) with better and advanced separation efficiency and detection limits.
{"title":"A Review on Comparison of HPLC and HPTLC","authors":"Sireesha Badri, Ravi Kumar J, Siva P, Pavan M, Basheer K, Ashok E, Lavanya B","doi":"10.37022/jiaps.v8i3.491","DOIUrl":"https://doi.org/10.37022/jiaps.v8i3.491","url":null,"abstract":"The analytical method should be sensitive, specific, fast and accurate to establish the assurance that the equipments used in manufacturing are free of the unwanted impurity, presence of which may alter the safety and efficacy of the drug product. HPLC, UPLC techniques have established their role in pharmaceutical cleaning validation. Among the modern Analytical tools HPTLC is a powerful analytical method equally suitable for qualitative and quantitative analytical tasks. HPTLC is playing an important role in today analytical world, not in competition to HPLC but as a complementary method. One of the most obvious orthogonal features of the two techniques is the primary use of reversed phases in HPLC versus unmodified silica gel in HPTLC, resulting in partition chromatography and adsorption chromatography respectively. High Performance Thin layer Chromatography (HPTLC) technique is a sophisticated and automated form of the thin-layer chromatography (TLC) with better and advanced separation efficiency and detection limits.","PeriodicalId":477216,"journal":{"name":"Journal of innovations in applied pharmaceutical sciences","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The convergence of Internet of Things (IoT) and blockchain technologies is catalysing a paradigm shift in the field of pharmacovigilance. This article provides an overview of the application of IoT and blockchain in pharmacovigilance, highlighting their transformative potential in enhancing patient safety and drug efficacy monitoring. IoT devices enable real-time data collection, enabling prompt identification of adverse events, while blockchain ensures data integrity and security. Together, they create a robust ecosystem for pharmacovigilance, allowing for transparent reporting, streamlined adverse event management, and proactive measures to safeguard public health. This paper explores key use cases, benefits, challenges, and prospects of this innovative approach, emphasizing its pivotal role in shaping the future of drug safety and regulatory compliance in the pharmaceutical industry.
{"title":"Catalyzing Drug Safety: Harnessing IoT and Block chain Technology and its Synergy in Pharmacovigilance","authors":"John Praveen","doi":"10.37022/jiaps.v8i3.478","DOIUrl":"https://doi.org/10.37022/jiaps.v8i3.478","url":null,"abstract":"The convergence of Internet of Things (IoT) and blockchain technologies is catalysing a paradigm shift in the field of pharmacovigilance. This article provides an overview of the application of IoT and blockchain in pharmacovigilance, highlighting their transformative potential in enhancing patient safety and drug efficacy monitoring. IoT devices enable real-time data collection, enabling prompt identification of adverse events, while blockchain ensures data integrity and security. Together, they create a robust ecosystem for pharmacovigilance, allowing for transparent reporting, streamlined adverse event management, and proactive measures to safeguard public health. This paper explores key use cases, benefits, challenges, and prospects of this innovative approach, emphasizing its pivotal role in shaping the future of drug safety and regulatory compliance in the pharmaceutical industry.","PeriodicalId":477216,"journal":{"name":"Journal of innovations in applied pharmaceutical sciences","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135303838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vesicular system drug design has revitalised the efficacy of previous medications by effectively regulating and sustaining their therapeutic action. The objective of this study is to evaluate the feasibility of utilizing pharmaceutical interventions to target novel vesicular drug delivery systems. The objective of innovative medication administration is to minimize adverse effects while ensuring drug efficacy at a predetermined or reasonably consistent level within the body. A novel drug delivery approach is characterized by the controlled release of medication at a predetermined rate, which is determined based on factors such as therapeutic requirements, pharmacological properties, drug characteristics, physiological condition of the organism, and other relevant considerations. At present, there is a lack of medication delivery technologies that effectively achieve the aforementioned objectives while minimizing adverse effects. The utilization of vesicular systems in drug delivery has brought about changes in the understanding and application of diagnosis and therapy across different domains within the biomedical field. The vesicular drug delivery system (VDDS) serves as a means to address the disparity between the theoretical ideal and the presently accessible innovative drug delivery systems, accomplishing this by enclosing active moieties within vesicular structures. Various vesicular drug delivery systems, such as liposomes, niosomes, transferases, pharmacosomes, colloidosomes, herbosomes, sphinosomes, among others, have been developed. This review primarily focuses on the examination of various pharmacological targets, both lipiodal and nonlipoidal, within vesicular systems. Liposomes and niosomes represent innovative drug delivery systems.
{"title":"A critical analysis of the vesicular drug delivery system: recent advancements and prospects for the future","authors":"Teja Kumar Reddy Konatham, Sahithi Alapati","doi":"10.37022/jiaps.v8i3.480","DOIUrl":"https://doi.org/10.37022/jiaps.v8i3.480","url":null,"abstract":"Vesicular system drug design has revitalised the efficacy of previous medications by effectively regulating and sustaining their therapeutic action. The objective of this study is to evaluate the feasibility of utilizing pharmaceutical interventions to target novel vesicular drug delivery systems. The objective of innovative medication administration is to minimize adverse effects while ensuring drug efficacy at a predetermined or reasonably consistent level within the body. A novel drug delivery approach is characterized by the controlled release of medication at a predetermined rate, which is determined based on factors such as therapeutic requirements, pharmacological properties, drug characteristics, physiological condition of the organism, and other relevant considerations. At present, there is a lack of medication delivery technologies that effectively achieve the aforementioned objectives while minimizing adverse effects. The utilization of vesicular systems in drug delivery has brought about changes in the understanding and application of diagnosis and therapy across different domains within the biomedical field. The vesicular drug delivery system (VDDS) serves as a means to address the disparity between the theoretical ideal and the presently accessible innovative drug delivery systems, accomplishing this by enclosing active moieties within vesicular structures. Various vesicular drug delivery systems, such as liposomes, niosomes, transferases, pharmacosomes, colloidosomes, herbosomes, sphinosomes, among others, have been developed. This review primarily focuses on the examination of various pharmacological targets, both lipiodal and nonlipoidal, within vesicular systems. Liposomes and niosomes represent innovative drug delivery systems.","PeriodicalId":477216,"journal":{"name":"Journal of innovations in applied pharmaceutical sciences","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136194178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tablets are currently the most widely used dosage form due to their ease of self-administration, compactness, and simple production. In many situations, rapid action is necessary rather than conventional therapy. Immediate release dosage forms have become an alternative to traditional oral dose forms in order to address these shortcomings. Immediately after administration, immediate medication release dose forms dissolve more quickly. Super disintegrants such carboxymethylcellulose (Croscarmellose), sodium starch glycolate (Primogel, Explotab), cross-linked polyvinylpyrrolidone (Polyplasdone), and others are employed as the fundamental method in the manufacture of tablets. After being administered to the stomach, these powerful disintegrants instantly dissolve tablets. In this area, parenteral dosage forms and instant release liquid dosage forms have both been introduced for the treatment of patients. It is possible to administer suspensions in liquid dose form using common dispersion agents as hydroxypropyl methylcellulose, AOT (dioctyl sulfosuccinate), etc. Many medications, including neuroleptics, cardiovascular medications, analgesics, antihistamines, and other medications, can be thought of as candidates for this dose form as a result of the advent of immediate release therapy. Pharmaceutical companies frequently create a certain medication entity in a new and improved dosage form as the drug entity's patent life is about to expire. While providing its patient group with a more practical dosage form or dosing schedule, a new dosage form enables a producer to extend market exclusivity.
{"title":"Formulation & evaluation of cyclodextrin complexed tablets by enhancing the dissolution rate","authors":"Gowtham Mandadapu, Prachertha Kolli, Venkata Gopaiah Kurra","doi":"10.37022/jiaps.v8i1.437","DOIUrl":"https://doi.org/10.37022/jiaps.v8i1.437","url":null,"abstract":"Tablets are currently the most widely used dosage form due to their ease of self-administration, compactness, and simple production. In many situations, rapid action is necessary rather than conventional therapy. Immediate release dosage forms have become an alternative to traditional oral dose forms in order to address these shortcomings. Immediately after administration, immediate medication release dose forms dissolve more quickly. Super disintegrants such carboxymethylcellulose (Croscarmellose), sodium starch glycolate (Primogel, Explotab), cross-linked polyvinylpyrrolidone (Polyplasdone), and others are employed as the fundamental method in the manufacture of tablets. After being administered to the stomach, these powerful disintegrants instantly dissolve tablets. In this area, parenteral dosage forms and instant release liquid dosage forms have both been introduced for the treatment of patients. It is possible to administer suspensions in liquid dose form using common dispersion agents as hydroxypropyl methylcellulose, AOT (dioctyl sulfosuccinate), etc. Many medications, including neuroleptics, cardiovascular medications, analgesics, antihistamines, and other medications, can be thought of as candidates for this dose form as a result of the advent of immediate release therapy. Pharmaceutical companies frequently create a certain medication entity in a new and improved dosage form as the drug entity's patent life is about to expire. While providing its patient group with a more practical dosage form or dosing schedule, a new dosage form enables a producer to extend market exclusivity.","PeriodicalId":477216,"journal":{"name":"Journal of innovations in applied pharmaceutical sciences","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136045824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：